Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 21

1.

Self-administered methoxyflurane for procedural analgesia: experience in a tertiary Australasian centre.

Gaskell AL, Jephcott CG, Smithells JR, Sleigh JW.

Anaesthesia. 2016 Apr;71(4):417-23. doi: 10.1111/anae.13377. Epub 2016 Feb 15.

2.

Clinical impact of IMPORT HIGH trial (CRUK/06/003) on breast radiotherapy practices in the United Kingdom.

Tsang Y, Ciurlionis L, Kirby AM, Locke I, Venables K, Yarnold JR, Titley J, Bliss J, Coles CE; IMPORT Trial Management Group..

Br J Radiol. 2015;88(1056):20150453. doi: 10.1259/bjr.20150453. Epub 2015 Oct 22.

3.

Neoadjuvant Long-Course Chemoradiotherapy for Rectal Cancer: Does Time to Surgery Matter?

Panagiotopoulou IG, Parashar D, Qasem E, Mezher-Sikafi R, Parmar J, Wells AD, Bajwa FM, Menon M, Jephcott CR.

Int Surg. 2015 Jun;100(6):968-73. doi: 10.9738/INTSURG-D-14-00192.1.

4.

High resolution anoscopy may be useful in achieving reductions in anal cancer local disease failure rates.

Goon P, Morrison V, Fearnhead N, Davies J, Wilson C, Jephcott C, Sterling J, Crawford R.

Eur J Cancer Care (Engl). 2015 May;24(3):411-6. doi: 10.1111/ecc.12168. Epub 2013 Dec 25.

PMID:
24373061
5.

Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial.

Mukherjee S, Hurt CN, Bridgewater J, Falk S, Cummins S, Wasan H, Crosby T, Jephcott C, Roy R, Radhakrishna G, McDonald A, Ray R, Joseph G, Staffurth J, Abrams RA, Griffiths G, Maughan T.

Lancet Oncol. 2013 Apr;14(4):317-26. doi: 10.1016/S1470-2045(13)70021-4. Epub 2013 Mar 6.

6.

Timing of surgery after neoadjuvant long-course chemoradiotherapy in the management of locally advanced rectal cancer.

Panagiotopoulou IG, Parashar D, Mezher-Sikafi R, Parmar J, Wells AD, Menon M, Jephcott CR.

Clin Oncol (R Coll Radiol). 2012 Dec;24(10):e195. doi: 10.1016/j.clon.2012.09.002. Epub 2012 Sep 20. No abstract available.

PMID:
22999843
7.

Common variation near CDKN1A, POLD3 and SHROOM2 influences colorectal cancer risk.

Dunlop MG, Dobbins SE, Farrington SM, Jones AM, Palles C, Whiffin N, Tenesa A, Spain S, Broderick P, Ooi LY, Domingo E, Smillie C, Henrion M, Frampton M, Martin L, Grimes G, Gorman M, Semple C, Ma YP, Barclay E, Prendergast J, Cazier JB, Olver B, Penegar S, Lubbe S, Chander I, Carvajal-Carmona LG, Ballereau S, Lloyd A, Vijayakrishnan J, Zgaga L, Rudan I, Theodoratou E; Colorectal Tumour Gene Identification (CORGI) Consortium., Starr JM, Deary I, Kirac I, Kovacević D, Aaltonen LA, Renkonen-Sinisalo L, Mecklin JP, Matsuda K, Nakamura Y, Okada Y, Gallinger S, Duggan DJ, Conti D, Newcomb P, Hopper J, Jenkins MA, Schumacher F, Casey G, Easton D, Shah M, Pharoah P, Lindblom A, Liu T; Swedish Low-Risk Colorectal Cancer Study Group., Smith CG, West H, Cheadle JP; COIN Collaborative Group., Midgley R, Kerr DJ, Campbell H, Tomlinson IP, Houlston RS.

Nat Genet. 2012 May 27;44(7):770-6. doi: 10.1038/ng.2293.

8.

Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial.

Adams RA, Meade AM, Seymour MT, Wilson RH, Madi A, Fisher D, Kenny SL, Kay E, Hodgkinson E, Pope M, Rogers P, Wasan H, Falk S, Gollins S, Hickish T, Bessell EM, Propper D, Kennedy MJ, Kaplan R, Maughan TS; MRC COIN Trial Investigators..

Lancet Oncol. 2011 Jul;12(7):642-53. doi: 10.1016/S1470-2045(11)70102-4. Epub 2011 Jun 5.

9.

Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial.

Maughan TS, Adams RA, Smith CG, Meade AM, Seymour MT, Wilson RH, Idziaszczyk S, Harris R, Fisher D, Kenny SL, Kay E, Mitchell JK, Madi A, Jasani B, James MD, Bridgewater J, Kennedy MJ, Claes B, Lambrechts D, Kaplan R, Cheadle JP; MRC COIN Trial Investigators..

Lancet. 2011 Jun 18;377(9783):2103-14. doi: 10.1016/S0140-6736(11)60613-2. Epub 2011 Jun 5.

10.

Quality of life after non-surgical treatment of anal carcinoma: a case control study of long-term survivors.

Jephcott CR, Paltiel C, Hay J.

Clin Oncol (R Coll Radiol). 2004 Dec;16(8):530-5.

PMID:
15630846
11.

Regional radiotherapy to axilla and supraclavicular fossa for adjuvant breast treatment: a comparison of four techniques.

Jephcott CR, Tyldesley S, Swift CL.

Int J Radiat Oncol Biol Phys. 2004 Sep 1;60(1):103-10.

PMID:
15337545
12.

Radiotherapy for craniopharyngioma in children: a national audit.

Jephcott CR, Sugden EM, Foord T.

Clin Oncol (R Coll Radiol). 2003 Feb;15(1):10-3.

PMID:
12602548
13.

Radiation-induced haemorrhagic cystitis.

Crew JP, Jephcott CR, Reynard JM.

Eur Urol. 2001 Aug;40(2):111-23. Review.

PMID:
11528186
14.

PRELIMINARY REPORT: A STUDY OF SILICOTIC LUNG ASHES.

JEPHCOTT CM, RIDDELL AR, KATZ M, SUTHERLAND RB.

Ind Med Surg. 1964 Apr;33:220-1. No abstract available.

PMID:
14136764
15.

Air pollution activities in Ontario.

JEPHCOTT CM.

Can J Public Health. 1960 Jun;51:235-9. No abstract available.

PMID:
14407146
16.

Determination of quartz of various particle sizes in quartz-silicate mixtures.

JEPHCOTT CM, WALL HF.

AMA Arch Ind Health. 1955 May;11(5):425-30. No abstract available.

PMID:
14360824
17.

Solubility of silica and alumina.

JEPHCOTT CM, JOHNSTON JH.

Arch Ind Hyg Occup Med. 1950 Mar;1(3):323-40. No abstract available.

PMID:
15426347
18.

Fume exposure in the manufacture of alumina abrasives; review of associated physical and chemical factors.

JEPHCOTT CM.

Occup Med (Chic Ill). 1948 Jun;5(6):701-9. No abstract available.

PMID:
18124573
19.

The fume exposure in the manufacture of alumina abrasives from bauxite.

JEPHCOTT CM, JOHNSTON JH, FINLAY GR.

J Ind Hyg Toxicol. 1948 May;30(3):145-59. No abstract available.

PMID:
18865916
20.

A STUDY OF THE CRYSTALLINE SILICEOUS MINERALS PRESENT IN SILICOTIC LUNGS BY THE X-RAY DIFFRACTION METHOD.

Jephcott CM, Gray WM, Irwin DA.

Can Med Assoc J. 1938 Mar;38(3):209-15. No abstract available.

Supplemental Content

Loading ...
Support Center